AR083780A1 - Composicion farmaceutica para tratar infecciones del hcv - Google Patents

Composicion farmaceutica para tratar infecciones del hcv

Info

Publication number
AR083780A1
AR083780A1 ARP110104143A ARP110104143A AR083780A1 AR 083780 A1 AR083780 A1 AR 083780A1 AR P110104143 A ARP110104143 A AR P110104143A AR P110104143 A ARP110104143 A AR P110104143A AR 083780 A1 AR083780 A1 AR 083780A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
hcv infections
treat hcv
poloxamer
composition containing
Prior art date
Application number
ARP110104143A
Other languages
English (en)
Inventor
Andreas Leiminer
Emmanuel Scheubel
Navnit Hargovindas Shah
Kai Lindenstruth
Dave Alan Miller
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR083780A1 publication Critical patent/AR083780A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Composición farmacéutica granulada que contiene un inhibidor de la proteasa del HCV y por lo menos un poloxámero.Reivindicación 1: Una composición farmacéutica granulada que contiene un compuesto de la fórmula (1), o una sal farmacéuticamente aceptable del mismo y por lo menos un poloxámero. Reivindicación 14: El uso de una composición según una cualquiera de las reivindicaciones de 1 a 10 para el tratamiento de infecciones de HCV.
ARP110104143A 2010-11-09 2011-11-07 Composicion farmaceutica para tratar infecciones del hcv AR083780A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10190461A EP2455068A1 (en) 2010-11-09 2010-11-09 Pharmaceutical composition for treating HCV infections

Publications (1)

Publication Number Publication Date
AR083780A1 true AR083780A1 (es) 2013-03-20

Family

ID=43561592

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110104143A AR083780A1 (es) 2010-11-09 2011-11-07 Composicion farmaceutica para tratar infecciones del hcv

Country Status (22)

Country Link
US (2) US20120114751A1 (es)
EP (2) EP2455068A1 (es)
JP (1) JP5841609B2 (es)
KR (1) KR20130095297A (es)
CN (1) CN103200934B (es)
AR (1) AR083780A1 (es)
AU (1) AU2011328307B2 (es)
BR (1) BR112013011405A2 (es)
CA (1) CA2812665C (es)
DK (1) DK2637643T3 (es)
ES (1) ES2529443T3 (es)
HK (1) HK1186982A1 (es)
IL (1) IL225302A (es)
MX (1) MX2013004685A (es)
MY (1) MY161769A (es)
PL (1) PL2637643T3 (es)
RU (1) RU2013125339A (es)
SG (1) SG189042A1 (es)
SI (1) SI2637643T1 (es)
TW (1) TWI436765B (es)
WO (1) WO2012062685A2 (es)
ZA (1) ZA201302438B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105990793B (zh) 2015-02-16 2018-03-27 西门子公司 包含吸附剂的电气装置
CN109280074A (zh) * 2017-07-20 2019-01-29 歌礼药业（浙江）有限公司 丹诺瑞韦钠晶体及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5281420A (en) * 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
DK0996429T3 (da) * 1997-10-27 2003-05-26 Merck Patent Gmbh Faste opløsninger og faste dispersioner i vand tungtopløselige lægemidler
US6632455B2 (en) 1997-12-22 2003-10-14 Schering Corporation Molecular dispersion composition with enhanced bioavailability
JPH11189548A (ja) * 1997-12-25 1999-07-13 Toshio Sato 無晶性医薬組成物及びその製造方法
JP4101661B2 (ja) * 2001-05-03 2008-06-18 エフ．ホフマン−ラ ロシュ アーゲー 非晶質メシル酸ネルフィナビルの製薬剤形
WO2005037214A2 (en) 2003-10-14 2005-04-28 Intermune, Inc. Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
JP2007517016A (ja) * 2003-12-31 2007-06-28 ファイザー・プロダクツ・インク 低溶解性薬剤及びポロキサマーの固体組成物
AU2005228894B9 (en) * 2004-03-30 2011-10-13 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
KR20080043852A (ko) * 2005-09-23 2008-05-19 에프. 호프만-라 로슈 아게 신규 투여 제형
PL1962808T3 (pl) * 2005-12-14 2011-03-31 Hoffmann La Roche Preparat proleku przeciw HCV
ATE462408T1 (de) * 2006-01-18 2010-04-15 Hoffmann La Roche Pharmazeutische zusammensetzungen, enthaltend valatograst, und verfahren zu deren herstellung
EP2142178B1 (en) * 2007-03-29 2012-01-11 F. Hoffmann-La Roche AG Pharmaceutical composition and process
JP2010526848A (ja) * 2007-05-11 2010-08-05 エフ．ホフマン−ラ ロシュ アーゲー 難溶性薬物用の医薬組成物
WO2010122087A1 (en) * 2009-04-25 2010-10-28 F. Hoffmann-La Roche Ag Methods for improving pharmacokinetics

Also Published As

Publication number Publication date
RU2013125339A (ru) 2014-12-20
CN103200934A (zh) 2013-07-10
IL225302A0 (en) 2013-06-27
DK2637643T3 (en) 2015-01-12
CN103200934B (zh) 2016-02-03
KR20130095297A (ko) 2013-08-27
AU2011328307B2 (en) 2016-04-21
BR112013011405A2 (pt) 2016-08-02
CA2812665C (en) 2018-12-18
ZA201302438B (en) 2021-05-26
MY161769A (en) 2017-05-15
PL2637643T3 (pl) 2015-05-29
US20120114751A1 (en) 2012-05-10
JP5841609B2 (ja) 2016-01-13
SG189042A1 (en) 2013-05-31
CA2812665A1 (en) 2012-05-18
MX2013004685A (es) 2013-09-26
EP2455068A1 (en) 2012-05-23
SI2637643T1 (sl) 2015-03-31
HK1186982A1 (zh) 2014-03-28
WO2012062685A2 (en) 2012-05-18
ES2529443T3 (es) 2015-02-20
TW201240660A (en) 2012-10-16
US20130331314A1 (en) 2013-12-12
JP2014500869A (ja) 2014-01-16
WO2012062685A3 (en) 2012-11-08
TWI436765B (zh) 2014-05-11
EP2637643B1 (en) 2014-12-17
EP2637643A2 (en) 2013-09-18
AU2011328307A1 (en) 2013-04-04
IL225302A (en) 2017-05-29

Similar Documents

Publication Publication Date Title
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
RS53209B (en) PHARMACEUTICAL COMPOSITION FOR VIRAL HEPATITIS C PROTEASE INHIBITOR
AR094966A1 (es) Composiciones farmacéuticas para el tratamiento de infecciones hcv
AR099632A1 (es) Tratamiento de una infección viral de hepatitis c, que usa una combinación de compuestos
EA200970805A1 (ru) Ингибиторы серинпротеаз для лечения hcv инфекций
UY33183A (es) Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento
UY30759A1 (es) Compuestos quimicos
PE20160180A1 (es) Combinaciones de compuestos que comprenden inhibidores de la integrasa de vih y otros agentes terapeuticos.
AR090456A1 (es) Combinaciones farmaceuticas que comprenden un analogo de tionucleotidos
CL2011002830A1 (es) Compuestos derivados de haloalquil heteroaril benzamidas; composicion farmaceutica uso de la composicion en el tratamiento de una infeccion viral, tal como el virus de la hepatitis b y c.
CO6511251A2 (es) Compuestos quimicos
UY30819A1 (es) Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
CL2011000589A1 (es) Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer.
CO6501153A2 (es) Inhibidores macrociclicos de serina proteasa
CL2011000558A1 (es) Formas cristalinas de un compuesto derivado de 2-tiazolil-4-quinolinil-oxi; sal de sodio del compuesto, composicion farmaceutica que comprende la sal de sodio, util para tratar una infeccion por el virus de la hepatitis c.
UY30437A1 (es) Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c
CL2012001959A1 (es) Compuestos derivados del acido tiofeno-2-carboxilico, inhibidores de virus flaviviridae; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion viral por flaviviridae.
AR077629A1 (es) Mimetico de smac
AR103680A1 (es) Inhibidores selectivos de bace1
ECSP109889A (es) Composiciones terapeuticas y usos de las mismas
CL2008002430A1 (es) Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc.
AR087107A1 (es) Compuesto inhibidor de la señalizacion de la trayectoria notch
CO2019002246A2 (es) Compuesto heterocíclico nitrogenado bicíclico

Legal Events

Date Code Title Description
FB Suspension of granting procedure